Early identification of patients with PsO who are at high risk of progressing to PsA is essential. Prof. Coates emphasised that addressing modifiable risk factors, such as nail disease and skin inflammation, as well as supporting weight loss in patients with elevated BMI may help reduce the risk of PsA. Additionally, emerging evidence suggests that early biologic treatment in PsO, before joint symptoms appear, may prevent PsA progression and limit long-term joint damage
